Eliquis 2.5 Mg

Eliquis 2.5 Mg (Apixaban)

Eliquis 2.5 Mg is a high-potency pharmacological intervention containing Apixaban, a highly selective, reversible, and direct inhibitor of Factor Xa. Specifically engineered for the clinical management of thromboembolic disorders, this formulation works by concurrently inhibiting free and clot-bound Factor Xa activity and modulating the prothrombinase complex. By neutralizing the biochemical triggers that facilitate the conversion of prothrombin to thrombin, Eliquis effectively facilitates the prevention of intravascular fibrin formation. This targeted biochemical action provides a decisive therapeutic response by reinforcing the structural uniformity of the coagulation cascade and promoting a stable, physiological blood flow without the requirement for routine international normalized ratio (INR) monitoring.

Key Features

• Specifically formulated at a 2.5mg concentration to target the rate-limiting step of the coagulation pathway.
• Clinically recognized for its role in reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
• Specifically engineered to provide a consistent anticoagulant effect with rapid absorption and a stable half-life.
• Acts as a functional catalyst to reduce the recurrence of pulmonary embolism (PE) and venous thromboembolism following orthopedic surgery.
• Formulated to address hypercoagulable states caused by various physiological and surgical risk factors.

Key Ingredients

• Apixaban (2.5mg)
• Lactose Anhydrous
• Microcrystalline Cellulose
• Croscarmellose Sodium
• Magnesium Stearate

Precautions

• This is a high-potency anticoagulant. Use must be strictly dictated by a healthcare professional after a full hematological and renal assessment.
• Strictly monitor for signs of internal or external bleeding (e.g., epistaxis, hematuria, or gastrointestinal bleeding), as anticoagulants increase the risk of hemorrhage.
• Consult your surgeon or cardiologist regarding the temporary cessation of Eliquis prior to invasive medical or dental procedures to manage bleeding risk.
• Use with caution in patients with significant renal impairment or hepatic dysfunction; dosage adjustments may be clinically required.
• Inform your specialist of all concurrent medications, particularly NSAIDs, antiplatelet agents, or inhibitors of CYP3A4 and P-gp, which may modulate anticoagulant efficacy.
• Keep the container tightly closed and store in a cool, dry place (below 25°C). Protect from moisture and excessive heat to maintain the stability of the active constituent.

How to Use

• The tablet should be swallowed whole with a glass of water. It may be administered with or without food.
• The standard dose is typically 2.5mg twice daily for specific indications, but the exact regimen must be specifically dictated by your healthcare professional based on age, weight, and renal function.
• For optimal clinical results, administration should occur at the same times each day (e.g., morning and evening) to maintain stable therapeutic plasma levels.
• If you miss a dose, take it as soon as possible on the same day and resume twice-daily administration. Do not double the dose to compensate for a missed one.
• Do not discontinue treatment without formal medical consultation, as premature cessation significantly increases the risk of thrombotic events.
• Maintain regular follow-ups with your physician to monitor the efficacy and systemic safety of the treatment.

Legal Disclaimer: Eliquis 2.5 Mg is a specialized pharmacological intervention for anticoagulation. Individual results and safety profiles vary based on the patient’s baseline renal health and underlying cardiovascular conditions. This product is for use under professional medical guidance only. This information is for educational purposes and is not a substitute for professional medical consultation or a formal clinical diagnosis.